HC Wainwright Reaffirms “Buy” Rating for BiomX (NYSEAMERICAN:PHGE)

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 170.45% from the stock’s previous close.

BiomX Stock Performance

Shares of NYSEAMERICAN:PHGE traded down $0.05 during midday trading on Wednesday, reaching $0.74. The company’s stock had a trading volume of 17,880 shares, compared to its average volume of 87,669. BiomX has a fifty-two week low of $0.48 and a fifty-two week high of $8.55. The firm has a market cap of $13.44 million, a PE ratio of -0.23 and a beta of 1.31.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).